Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
Olivier Govaere, Simon Cockell, DINA G. TINIAKOS et al. · Science Translational Medicine · 2020
, whereas GDF15 supplementation tempered the inflammatory response in macrophages upon lipid loading and lipopolysaccharide stimulation. This study provides insights into the pathophysiology of progressive fibrosing steatohepatitis, and proof of principle that transcriptomic changes represent potentially tractable and clinically relevant markers of disease progression.
Cited by 471 works. doi:10.1126/scitranslmed.aba4448 Open-access PDF
Authors
- Olivier Govaere
- Simon Cockell
- DINA G. TINIAKOS
- Rachel A. Queen
- Ramy Younes
- Michèle Vacca
- Leigh E. Alexander
- Federico Ravaioli
- Jeremy M. Palmer
- Salvatore Petta
- Jérôme Boursier
- Chiara Rosso
- Katherine Johnson
- Kristy Wonders
- Christopher Paul Day
- Mattias Ekstedt
- Matej Orešič
- Rebecca Darlay
- Heather Jane Cordell
- Fabio Marra
References
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- Statistical significance for genomewide studies
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
- Robust enumeration of cell subsets from tissue expression profiles
- Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
- Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management